Journey Medical Corporation (DERM) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: 53.48
30Y Low53.5·High53.5
P/FCF
N/A
—
5yr avg: 437.58
P/B Ratio
↑
4.78
↑+24% vs avg
5yr avg: 3.85
30Y Low2.0·High5.9
ROE
↑
-44.0%
↓+46% vs avg
5yr avg: -81.2%
30Y Low-315%·High132%
Debt/EBITDA
N/A
—
5yr avg: 9.95
30Y Low0.8·High9.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DERM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Journey Medical Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $171M | $189M | $80M | $105M | $34M | $93M | — | — | — | — | — |
| Enterprise Value | $147M | $165M | $85M | $95M | $25M | $45M | — | — | — | — | — |
| P/E Ratio → | -13.23 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.77 | 3.05 | 1.42 | 1.33 | 0.46 | 1.48 | — | — | — | — | — |
| P/B Ratio | 4.78 | 5.93 | 3.98 | 5.16 | 1.98 | 2.22 | — | — | — | — | — |
| P/FCF | — | — | — | 437.58 | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 20.04 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DERM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.67 | 1.52 | 1.20 | 0.33 | 0.71 | — | — | — | — | — |
| EV / EBITDA | — | — | — | 53.48 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | 397.12 | — | — | — | — | — | — | — |
DERM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Journey Medical Corporation earns an operating margin of -13.2%. Operating margins have compressed from -2.6% to -13.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -44.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.3% | 59.3% | 62.8% | 66.3% | 58.2% | 49.2% | 67.2% | 69.8% | 97.2% | 100.0% | 100.0% |
| Operating Margin | -13.2% | -13.2% | -24.4% | -2.6% | -37.4% | -55.2% | 17.6% | 15.1% | -505.4% | -6613.7% | -401.3% |
| Net Profit Margin | -18.5% | -18.5% | -26.1% | -4.9% | -40.2% | -69.7% | 11.9% | 10.4% | -523.3% | -6678.3% | -394.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.0% | -44.0% | -72.6% | -20.6% | -100.4% | -168.1% | 81.0% | 131.7% | -315.1% | -152.8% | -41.2% |
| ROA | -13.1% | -13.1% | -18.7% | -4.2% | -29.3% | -59.0% | 12.3% | 1.9% | -49.0% | -69.4% | -33.3% |
| ROIC | -36.8% | -36.8% | -56.8% | -16.7% | -2272.9% | -895.6% | 77.4% | 3.9% | -96.4% | -133.0% | -47.9% |
| ROCE | -16.0% | -16.0% | -34.2% | -5.7% | -65.5% | -100.3% | 42.7% | 3.3% | -56.2% | -81.9% | -38.3% |
DERM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $24M exceeds total debt of $119000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 1.28 | 0.87 | 1.35 | 0.02 | 0.96 | 1.93 | — | 1.87 | — |
| Debt / EBITDA | — | — | — | 9.95 | — | — | 1.07 | 0.82 | — | — | — |
| Net Debt / Equity | — | -0.75 | 0.27 | -0.48 | -0.53 | -1.15 | 0.16 | 0.18 | — | -0.11 | -0.17 |
| Net Debt / EBITDA | — | — | — | -5.45 | — | — | 0.18 | 0.08 | — | — | — |
| Debt / FCF | — | — | — | -40.45 | — | — | 0.43 | 0.08 | — | — | — |
| Interest Coverage | -2.21 | -2.21 | -4.41 | -1.14 | -13.64 | -5.02 | 11.25 | 20.62 | -13.18 | -36.26 | -56.85 |
Net cash position: cash ($24M) exceeds total debt ($119000)
DERM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.79x means Journey Medical Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 1.35x to 1.79x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.79 | 1.79 | 1.37 | 1.35 | 1.16 | 1.64 | 1.26 | 1.21 | 8.70 | 5.28 | 8.12 |
| Quick Ratio | 1.53 | 1.53 | 0.96 | 1.10 | 0.95 | 1.45 | 1.21 | 1.17 | 8.48 | 5.28 | 8.12 |
| Cash Ratio | 0.64 | 0.64 | 0.58 | 0.66 | 0.48 | 0.95 | 0.29 | 0.23 | 8.12 | 5.23 | 7.20 |
| Asset Turnover | — | 0.65 | 0.70 | 1.03 | 0.70 | 0.65 | 0.86 | 1.03 | 0.12 | 0.01 | 0.07 |
| Inventory Turnover | 2.62 | 2.62 | 1.45 | 2.61 | 2.17 | 3.25 | 10.39 | 12.29 | 0.14 | — | — |
| Days Sales Outstanding | — | 175.74 | 66.53 | 70.17 | 139.76 | 133.62 | 196.13 | 198.12 | 49.35 | 4.18 | 345.85 |
DERM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Journey Medical Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | 0.2% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 1.1% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 1.1% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $24M | $20M | $18M | $18M | $17M | $17M | $17M | $42M | $41M | $33M |
Peer Comparison
Compare DERM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DERMYou | $171M | -13.2 | — | — | 59.3% | -13.2% | -44.0% | -36.8% | — |
 SKIN | $86M | -4.1 | 51.0 | 2.3 | 65.3% | -6.9% | -16.9% | -6.8% | 83.3 |
 PRGO | $1B | -1.0 | 7.1 | 9.8 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 PODD | $10B | 41.9 | 18.0 | 27.1 | 71.6% | 17.5% | 18.1% | 20.1% | 1.8 |
 VYNE | $27M | -1.0 | — | — | 96.0% | -5219.1% | -66.3% | -124.0% | — |
 PCRX | $878M | 139.6 | 9.4 | 6.4 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 MCK | $90B | 19.6 | 13.2 | 15.8 | 3.6% | 1.6% | — | 254.1% | 1.2 |
 CAH | $52B | 34.4 | 18.8 | 28.2 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
 HSIC | $9B | 24.4 | 11.9 | 16.0 | 29.1% | 5.7% | 8.3% | 7.1% | 3.4 |
 ACRS | $543M | -8.5 | — | — | 73.3% | -975.9% | -50.2% | -53.0% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
DERM — Frequently Asked Questions
Quick answers to the most common questions about buying DERM stock.
What is Journey Medical Corporation's P/E ratio?
Journey Medical Corporation's current P/E ratio is -13.2x. This places it at the 50th percentile of its historical range.
What is Journey Medical Corporation's ROE?
Journey Medical Corporation's return on equity (ROE) is -44.0%. The historical average is -64.1%.
Is DERM stock overvalued?
Based on historical data, Journey Medical Corporation is trading at a P/E of -13.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Journey Medical Corporation's profit margins?
Journey Medical Corporation has 59.3% gross margin and -13.2% operating margin.